US Drug Patent 11,571,478: Claim Scope, Patent Strength, Exclusivity and Competitive Landscape

US Patent No. 11,571,478 protects a narrowly defined photodynamic therapy protocol using topical 5-aminolevulinic acid, a low-density polyethylene occlusive barrier, at least 65% occlusion, removal after three hours, and subsequent light treatment. The patent does not broadly cover ALA, photodynamic therapy, topical ALA compositions, or all occlusive dressings. Its commercial value depends on whether a competing product or provider uses the specified polyethylene barrier and treatment sequence.

The patent claims a method of use rather than a composition, device, or manufacturing process. Claims 1, 17, and 18 are the principal independent claims. Claims 2 through 16 add narrower limitations involving occlusion levels, barrier placement, heating, formulation, application technique, lesion type, and illumination.

What does US Patent 11,571,478 protect?

The core protected method requires all of the following:

Required element	Claim requirement
Active agent	Topical 5-aminolevulinic acid, or ALA
Treatment	Photodynamic therapy
Application	ALA is topically applied to a treatment area
Barrier	Low-density polyethylene barrier
Timing	Barrier is applied after ALA application and before light treatment
Occlusion	At least 65% degree of occlusion
Incubation	Barrier is removed after three hours
Illumination	Light is applied after barrier removal

Claim 1 is the principal broad claim. It covers a treatment protocol only when each limitation is practiced. A method using a non-polyethylene occlusive film, a barrier removed before three hours, or an occlusion level below 65% would fall outside the literal language of claim 1 unless a court applied the doctrine of equivalents.

The patent is therefore narrower than a conventional “ALA plus occlusion” patent. The required material, measured occlusion level, incubation period, and sequence create the main infringement boundaries.

How do claims 1, 17, and 18 differ?

Claim 1: Base occlusion method

Claim 1 requires the polyethylene barrier, at least 65% occlusion, removal after three hours, and light treatment after removal. It does not expressly require or prohibit heating.

Claim 17: Non-heated alternative

Claim 17 repeats the core method and adds the limitation that the treatment area is not heated before illumination. This claim is narrower than claim 1 but may remain relevant where a provider deliberately avoids pre-illumination heating.

Claim 18: Two-layer barrier

Claim 18 requires a two-layer barrier in which the top layer provides light pressure to keep the lower layer in place. This claim targets a specific physical arrangement rather than a general occlusive dressing.

The relationship between claims 1, 16, and 17 creates two practical pathways:

Claim 16 covers heating the treatment area by about 2°C before light treatment.
Claim 17 covers treatment without pre-illumination heating.
Claim 1 remains broader because it does not expressly require either condition.

What do the dependent claims add?

Claim	Added limitation	Commercial significance
2	At least 75% occlusion	Covers more complete occlusion
3	At least 85% occlusion	Covers highly occlusive treatment
4	Barrier contacts treatment area	Excludes a spaced or non-contact barrier
5	Barrier conforms closely to treatment surface	Targets fitted application
6	Elastic net holds barrier in place	Covers a specific retention technique
7	Barrier is covered with material	Adds an outer covering
8	Material is placed over and around barrier	Specifies outer-covering configuration
9	Barrier removed within 3 hours 18 minutes	Creates a narrow timing window
10	Treatment area is wet when covered	Adds a pretreatment condition
11	Topical composition is a gel	Limits the formulation
12	Light is red light	Targets red-light PDT systems
13	ALA is applied digitally	Covers finger or hand application
14	ALA is applied with a handheld device	Covers applicator-based administration
15	Treatment area includes actinic keratosis	Targets the principal dermatology indication
16	Treatment area heated by about 2°C	Covers a mild heating step
17	Treatment area is not heated	Covers the non-heated protocol
18	Two-layer barrier with top-layer pressure	Covers a particular barrier structure

Claims 2 and 3 are not separate broad inventions. They are fallback claims that preserve protection if the at-least-65% limitation in claim 1 is challenged or construed narrowly. Claims 4 through 10 focus on how the dressing is applied and retained. Claims 11 through 16 tie the method to common clinical implementation details.

What is the practical claim scope for competing ALA products?

A competing ALA photodynamic therapy product could avoid literal infringement by changing one or more material elements of the protocol.

Design-around approach	Likely effect on claim exposure
Use a non-LDPE barrier	Potentially avoids the express polyethylene limitation
Use a barrier removed before three hours	Potentially avoids the timing limitation
Use no barrier	Avoids the barrier and occlusion limitations
Use occlusion below 65%	Potentially avoids claim 1
Use illumination before barrier removal	Conflicts with the claimed sequence
Use a different active agent	Avoids the ALA limitation
Use a non-topical route	Avoids the topical-application limitation
Use a composition without a gel	Avoids claim 11, but not necessarily claim 1
Use blue light rather than red light	Avoids claim 12, but not necessarily claim 1
Apply ALA with a different technique	May avoid claims 13 and 14 only
Heat substantially outside the “about 2°C” limitation	May avoid claim 16, subject to claim construction

The strongest design-around is usually a change to the barrier material or the three-hour incubation requirement. Changing the applicator, gel status, light wavelength, or heating condition may avoid dependent claims while leaving claim 1 potentially relevant.

The material limitation is especially important. “Low density polyethylene” is narrower than “polyethylene” and materially narrower than “occlusive film.” A multilayer dressing could present a construction issue if only one layer is LDPE, particularly under claim 18.

How should the occlusion limitation be analyzed?

The patent claims a “degree of occlusion” of at least 65%, with dependent thresholds of 75% and 85%. The claims supplied do not define the measurement method. That creates a central enforcement and validity issue.

A commercial implementation would need to assess:

Whether occlusion is measured by water-vapor transmission, transepidermal water loss, humidity retention, or another metric.
Whether the measurement applies to the barrier material, the assembled dressing, or the treatment area.
Whether the percentage is an average, minimum, or area-specific value.
Whether pressure, edge leakage, wrinkles, and barrier conformity affect the result.
Whether “at least 65%” is measured before or during the three-hour incubation.

Claims 5 and 10 reinforce the importance of physical application conditions. A barrier that conforms closely to the skin and is applied to a wet treatment area may generate a different occlusion result from the same film used loosely or over dry skin.

This limitation can strengthen non-infringement positions but may weaken enforcement if the patent specification does not provide a reproducible test protocol. It may also create an indefiniteness or enablement issue if skilled practitioners cannot determine whether a protocol reaches the claimed threshold.

What formulations and light systems are covered?

The broad independent claims do not require a gel or red light. They cover a topical ALA composition and light treatment generally.

The dependent claims narrow the field:

Claim 11 covers a gel formulation.
Claim 12 covers red light.
Claim 15 covers actinic keratosis.
Claim 16 covers mild pre-illumination heating.
Claim 17 covers the absence of heating.

The claims therefore reach common dermatology implementations without making every implementation dependent on one formulation or wavelength. A product using an ALA gel and red light may implicate claims 1, 11, and 12 if the polyethylene, occlusion, and timing requirements are also met.

The patent does not, based on the supplied claims, protect:

The chemical synthesis of ALA.
A particular ALA salt or ester.
A proprietary ALA gel composition as such.
A light-emitting diode device.
A specific red-light wavelength range.
A particular commercial applicator as a device.
Manufacturing of the polyethylene barrier.

Those subjects would require separate composition, device, formulation, or manufacturing claims.

How does the patent compare with existing ALA photodynamic therapy products?

The principal U.S. ALA PDT products are LEVULAN KERASTICK and AMELUZ. LEVULAN contains aminolevulinic acid hydrochloride and is approved for actinic keratoses using photodynamic therapy. AMELUZ is a topical aminolevulinate hydrochloride gel used with photodynamic therapy for actinic keratoses. Their FDA-approved labeling defines the approved product, application, incubation, and illumination procedures. [2], [3]

Product	Active ingredient	Dosage form	Principal U.S. use	Relevance to Patent 11,571,478
LEVULAN KERASTICK	Aminolevulinic acid hydrochloride	Topical solution generated by applicator	Actinic keratosis PDT	Exposure depends on whether the commercial protocol uses the claimed LDPE barrier and timing
AMELUZ	Aminolevulinate hydrochloride	Topical gel	Actinic keratosis PDT	Gel and red-light implementations may implicate claims 1, 11, and 12 if the claimed barrier protocol is used
Other ALA products	ALA or ALA derivative	Product-specific	Dermatology and PDT indications	Must be assessed against the barrier, occlusion, and timing limitations

FDA approval of an ALA product does not itself establish infringement. Infringement depends on the approved label, actual provider instructions, product training materials, promotional conduct, and the treatment protocol used in practice.

What is the Orange Book status of US Patent 11,571,478?

A patent’s inclusion in the FDA Orange Book is separate from its validity and infringement status. The Orange Book lists patents submitted for approved drug products under the applicable FDA procedures. Method-of-use patents may be listed when they satisfy FDA requirements, but a patent number cannot be treated as Orange Book-listed solely because it covers a method involving an approved drug. [4]

The supplied claim text does not establish that US 11,571,478 is listed against LEVULAN KERASTICK, AMELUZ, or another approved ALA product. The patent is a method patent, and any Orange Book relevance would depend on the specific NDA submission and FDA listing record.

If listed against an NDA, a generic applicant could face a Paragraph IV certification. If not listed, a Paragraph IV challenge to this patent would not arise through the Orange Book certification mechanism, although the patent could still be asserted in district court.

When does US Patent 11,571,478 lose exclusivity?

The patent issued on February 7, 2023. The expiration date cannot be calculated from the claims alone because U.S. patent term depends on the earliest effective nonprovisional filing date, any terminal disclaimer, patent-term adjustment, and any patent-term extension. The patent term is generally 20 years from the earliest effective nonprovisional filing date, subject to statutory adjustments. [1], [5]

Exclusivity item	Status based on the supplied record
Grant date	February 7, 2023
Patent type	Utility patent
Claim category	Method of treatment
Expiration date	Not determinable from claim text alone
Patent-term adjustment	Not established from claim text
Patent-term extension	No conclusion from claim text
Pediatric exclusivity	Not applicable to the patent itself
Regulatory exclusivity	Separate from patent term

A patent expiration date should be taken from the USPTO patent record and terminal-disclaimer information, not inferred from the grant date.

What Paragraph IV challenges and generic entry risks exist?

The relevant challenger would usually be a generic or follow-on applicant seeking approval for an ALA product covered by an NDA. The risk analysis has two separate layers.

Product-level risk

A generic applicant may certify that the patent is not listed, has expired, is not infringed, or is invalid. A Paragraph IV notice could trigger a Hatch-Waxman lawsuit and a statutory stay of FDA approval under the conditions set out in the Federal Food, Drug, and Cosmetic Act. [6]

Label and method-of-use risk

The patent’s claims require a particular treatment protocol. A generic applicant may pursue a restricted label that omits the claimed use or instructions. That strategy is effective only if the proposed label, marketing conduct, and foreseeable use do not induce infringement.

The principal generic entry scenarios are:

Full protocol substitution. The generic uses the same LDPE barrier, at least 65% occlusion, three-hour incubation, and post-removal illumination. This presents the highest infringement exposure.
Barrier substitution. The generic uses a different material or a dressing whose LDPE content is not part of the patient-facing protocol. This is the most direct design-around.
Timing substitution. The generic uses a materially shorter or longer incubation period.
Label carve-out. The generic omits the claimed occlusion protocol while retaining other approved ALA uses.
Non-infringing clinical use. The product is approved, but providers use it without the claimed barrier configuration.

The patent creates a method-of-use barrier, not necessarily a complete barrier to approval of every ALA generic.

How strong is the patent estate?

Strengths

The claims identify a specific clinical sequence.
The LDPE requirement may distinguish the patent from broad ALA or generic occlusion prior art.
Claims cover both heated and non-heated pathways.
Dependent claims provide fallback positions on occlusion, gel formulation, red light, actinic keratosis, and dressing structure.
The protocol can potentially be enforced against providers, clinics, product sponsors, or parties inducing the claimed use.

Vulnerabilities

The claims are dependent on a narrow material limitation.
“Degree of occlusion” may require a clear and reproducible measurement standard.
Three-hour timing may be difficult to prove in routine clinical use.
Prior art involving ALA, occlusive films, incubation, and PDT may create anticipation or obviousness arguments.
The claims do not independently protect the ALA product or light device.
A competitor may design around the barrier, timing, or occlusion threshold.

The estate is best characterized as a targeted method patent with moderate blocking potential for a specific treatment protocol. It is not a platform patent covering the ALA PDT market.

What patent litigation affects US Patent 11,571,478?

No litigation, settlement agreement, Paragraph IV case, or license can be established from the claim text supplied. A litigation assessment requires comparison against the USPTO assignment and maintenance records, federal court dockets, FDA Orange Book data, and any publicly disclosed licensing or settlement agreements.

The most likely litigation theories would involve:

Literal infringement of claim 1.
Induced infringement based on product labeling or clinical instructions.
Claim construction of “low density polyethylene.”
Measurement of the “degree of occlusion.”
Interpretation of “after 3 hours.”
Enablement and written-description challenges.
Obviousness based on known ALA PDT and occlusive dressing protocols.

What geographic coverage does the patent provide?

US Patent 11,571,478 provides rights in the United States only. It does not by itself protect the same method in Europe, Canada, Japan, China, Australia, or other jurisdictions.

International exposure depends on corresponding national applications or grants. Patent-family members may have different claim scope, expiration dates, prosecution histories, and validity outcomes. A U.S. competitor can face U.S. method infringement risk even if the same protocol is unprotected abroad.

Key Takeaways

US Patent 11,571,478 is a narrow method-of-treatment patent for ALA photodynamic therapy.
Claim 1 requires topical ALA, an LDPE barrier, at least 65% occlusion, removal after three hours, and subsequent light treatment.
Claims 17 and 18 protect non-heated treatment and a two-layer barrier configuration.
The patent does not broadly cover ALA, ALA gels, red-light devices, or all occlusive PDT protocols.
The central technical issues are LDPE identification, occlusion measurement, and the three-hour timing requirement.
AMELUZ and LEVULAN are commercially relevant comparator products, but product approval alone does not establish infringement.
Orange Book listing, Paragraph IV exposure, patent expiration, licensing, and litigation status are not established by the claim text.
The principal generic design-arounds are use of a different barrier material, altered incubation timing, lower occlusion, or a label that omits the claimed protocol.
The patent has targeted commercial value but does not appear, from the supplied claims, to create a complete barrier to all ALA photodynamic therapy competition.

FAQs

Does the patent cover any polyethylene dressing?

No. The claims specify a low-density polyethylene barrier. A dressing made from another polymer may avoid literal infringement, although multilayer products and the doctrine of equivalents may create claim-construction issues.

Can a competitor use ALA with a barrier for less than three hours?

A protocol removed materially before three hours may avoid the express timing limitation in the independent claims. The precise result depends on how “after 3 hours” is construed and whether other patent claims or patent-family members apply.

Does claim 12 cover all red-light photodynamic therapy?

No. Claim 12 is a dependent claim. It adds red light to the method of claim 1. Red light alone does not satisfy the LDPE, occlusion, timing, and ALA requirements.

Is claim 17 relevant if the treatment area is naturally warm?

Potentially. Claim 17 excludes heating before light treatment, but the scope of “heated” would depend on whether the temperature change resulted from an intentional treatment step or ordinary environmental conditions.

Does the patent protect a two-layer medical dressing as a product?

No. Claim 18 is a method claim. It protects use of a two-layer barrier in the specified ALA PDT protocol, not the dressing as a standalone product.

References

United States Patent and Trademark Office. (2023). U.S. Patent No. 11,571,478.
U.S. Food and Drug Administration. (n.d.). LEVULAN KERASTICK for topical solution prescribing information.
U.S. Food and Drug Administration. (n.d.). AMELUZ prescribing information.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
35 U.S.C. §§ 154, 156.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm Inds Inc	LEVULAN	aminolevulinic acid hydrochloride	SOLUTION;TOPICAL	020965-001	Dec 3, 1999		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF ACTINIC KERATOSIS OF UPPER EXTREMITIES BY PHOTODYNAMIC THERAPY	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019200152	⤷ Start Trial
Australia	2020103365	⤷ Start Trial
Australia	2020267186	⤷ Start Trial
Australia	2021102111	⤷ Start Trial
Australia	2021107564	⤷ Start Trial
Australia	2022209242	⤷ Start Trial
Australia	2024205278	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,571,478

Which drugs does patent 11,571,478 protect, and when does it expire?

Summary for Patent: 11,571,478